Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nuclear prelamin A recognition factor (NARF) is a nuclear protein that specifically binds to the prenylated C-terminal tail domain of prelamin A, a precursor of lamin A. Its binding depends on the farnesylation status of prelamin A, making it an example of prenyl-dependent protein-protein interaction. NARF partially colocalizes with the nuclear lamina and may be part of a prelamin A endoprotease complex involved in lamin A maturation. Recent studies have uncovered a role for NARF as a transcriptional coactivator in hypoxic breast cancer cells, where it enhances stemness and metastatic features by epigenetically upregulating pluripotency factor genes. Additionally, NARF has been linked to mitochondrial dysfunction and iron metabolism dysregulation in neurological disease contexts such as multiple sclerosis. Structurally, NARF shows limited sequence similarity to iron-only bacterial hydrogenases, and several transcript variants exist due to alternative splicing and RNA editing
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nuclear prelamin A recognition factor (NARF).